Member access

4-Traders Homepage  >  Shares  >  Euronext Alternext  >  NEOVACS    ALNEV   FR0004032746

NEOVACS

 (ALNEV)
98
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
05/17/2013 05/20/2013 05/21/2013 05/22/2013 05/23/2013 Date
1.91(c) 1.9(c) 1.91(c) 1.92(c) 1.86(c) Last
273 751 58 724 129 119 97 669 96 376 Volume
+3.24% -0.52% +0.53% +0.52% -3.13% Change
More quotes
Company
Neovacs specializes in developing active immunotherapies for treating auto-immune, inflammatory, and cancerous diseases. At the end of 2011, the group had a portfolio of 3 products, including 1 in preclinical development phase (VEGF-K; treatment of cancer and age-related macular degeneration) and... 
Read more
Sector
Biotechnology
Calendar
06/10 | 04:00amShareholder meeting
Surperformance© rating of NEOVACS
Trading Rating : Investor Rating : -
More about the company
Chart NEOVACS
Duration : Period :
NEOVACS Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Full-screen chart
Financials (€)
Sales 2013 -
EBIT 2013 -8,46 M
Net income 2013 -7,14 M
Finance 2013 0,19 M
Yield 2013 -
Sales 2014 -
EBIT 2014 -8,58 M
Net income 2014 -7,51 M
Debt 2014 4,11 M
Yield 2014 -
PER 2013 -
PER 2014
EV / Sales 2013 0
EV / Sales 2014 0
Capitalization 37,8 M
More Financials
Latest news on NEOVACS
05/13 NEOVACS: Receives Payment of ?415K from Oséo for the Tracker Programme
04/22 NEOVACS: Science Publishes 2 Articles of Direct Relevance to Neovacs Clinical R..
03/29 NEOVACS: 29 March 2013 - Financial Results for 2012 :
03/29 NEOVACS: Financial Results for 2012
03/21 NEOVACS: Total Number of Voting Rights and Shares
03/12 NEOVACS: Success of the neovacs capital increase offering oversubscribed by 35%..
02/15 NEOVACS: 15 February 2013 - Neovacs launches a capital increase :
02/07 NEOVACS: 07 February 2013 - Publication in the Journal Arthritis & Rheumatism o..
02/07 NEOVACS: Publication in the Journal Arthritis & Rheumatism of an Article on Act..
01/14 NEOVACS: Half-Year Report on the Liquidity Contract
2012 NEOVACS: 20 November 2012 - Final Results of Phase II study in Crohn's Disease ..
2012 NEOVACS: Final Results of the Phase II Study in Crohn's
More news
Forum NEOVACS
Be the first to post a message on NEOVACS
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Technical analysis
Income Statement Evolution
NEOVACS : Income Statement Evolution
More Financials
EPS Revisions
NEOVACS : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF
My Watchlist|My Portfolio
4-traders.com :
About :
Copyright © 2013 Surperformance. All rights reserved.